Stock Taper
SCREENER COMPARE ANY 2 STOCKS
SPRC
SCISPARC LTD.
NASDAQ
$5.08
▲ UP 2.63% (0.13)

KEY STATISTICS

Market Cap$300.12 K
52w High$80.10
52w Low$2.98
Dividend Yield—
Frequency—
P/E-0.03
Volume11.58K
Shares Out.57.84K

COMPANY

LEADERSHIP

Oz Adler
CHIEF EXECUTIVE
Oz Adler

ABOUT

SECTOR
Healthcare
WENT PUBLIC
August 30, 2021
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
3

SPLIT RECORD

DATETYPERATIO
2026-03-04Reverse1:9
2025-07-03Reverse1:21
2023-09-28Reverse1:26

PRICE

$5.08 ▲ UP 2.63% (+$0.13)
OVERLAYS
$5.00$5.10$5.209:46 AM10:48 AM11:50 AM12:53 PM1:55 PM2:57 PM3:59 PM5.08

About SciSparc Ltd.

https://scisparc.com ↗

SciSparc Ltd. is a Tel Aviv-based clinical-stage pharma company developing cannabinoid-based drugs for conditions like Tourette’s, sleep apnea, Alzheimer’s, pain, autism, and epilepsy, with multiple clinical trials and partnerships.

INDUSTRY

Biotechnology

A PRODUCT SCISPARC LTD. IS KNOWN FOR

MUSE™ system
MUSE™ system

The MUSE™ system is a single-use endoscopic device for minimally invasive transoral fundoplication to treat GERD, marking SciSparc’s entry into the $billion medical device market with commercialization planned after acquiring its IP in January 2026.

COMPETITORS

COMPETITOR
JNJ COMPARE
MDT COMPARE
MMSI COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
6
LISTED HERE
1
RANKED BY POSITION SIZE
AVEM
0.00% · 2.7M

INSTITUTIONAL OWNERSHIP

SHARES OWNED
0.00%
HOLDERS
1
TOP 1 OF 1 · RANKED BY POSITION SIZE
Ahrens Investment Partners LLC
1 sh · $0

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book5
Overall Score2

INSIDER TRADES

★
DIRECTOR
Weiss Amitay
— · 6 shares
2022-01-03
★
DIRECTOR
Shrem Itschak
— · 6 shares
2022-01-03
★
DIRECTOR
Sidi Liat
— · 1 shares
2022-01-03
★
DIRECTOR
Vider Lior
— · —
2026-03-18

SECTORS PEERS

PEERPRICE
INDP$2.62COMPARE
JSPR$0.69COMPARE
ONCO$0.74COMPARE
ARTL$5.74COMPARE
PTIX$0.87COMPARE
SLXN$0.35COMPARE
LIPO$0.00COMPARE
SCNI$1.75COMPARE